<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>ar646</ui>
   <ji>ARJ</ji>
   <fm>
      <dochead>Meeting abstract</dochead>
      <bibl>
         <title>
            <p>The diagnostic significance of autoantibodies in patients with very early rheumatoid arthritis</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Nell</snm>
               <fnm>V</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A2">
               <snm>Machold</snm>
               <fnm>K</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A3">
               <snm>Hueber</snm>
               <fnm>W</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A4">
               <snm>Eberl</snm>
               <fnm>G</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A5">
               <snm>Hiesberger</snm>
               <fnm>H</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A6">
               <snm>Hoefler</snm>
               <fnm>E</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A7">
               <snm>Smolen</snm>
               <fnm>J</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A8">
               <snm>Steiner</snm>
               <fnm>G</fnm>
               <insr iid="I1"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Division of Rheumatology, University Hospital of Vienna, Lainz Hospital, Vienna, Austria</p>
            </ins>
         </insg>
         <source>Arthritis Res Ther</source>
         <supplement>
            <title>
               <p>23rd European Workshop for Rheumatology Research</p>
            </title>
            <sponsor>
               <note>The organizer would like to thank the following companies who have generously supported the 23rd European Workshop for Rheumatology Research: Abbott, Amgen, Aventis, Merck Sharp and Dohme, Novartis, Pharmacia, Schering-Plough, Wyeth</note>
            </sponsor>
            <note>Meeting abstracts</note>
         </supplement>
         <conference>
            <title>
               <p>23rd European Workshop for Rheumatology Research</p>
            </title>
            <location>Marseille, France</location>
            <date-range>27 February &#8211; 2 March 2003</date-range>
         </conference>
         <issn>1478-6354</issn>
         <pubdate>2003</pubdate>
         <volume>5</volume>
         <issue>Suppl 1</issue>
         <fpage>16</fpage>
         <xrefbib>
            <pubid idtype="doi">10.1186/ar646</pubid>
         </xrefbib>
      </bibl>
      <history>
         <pub>
            <date>
               <day>24</day>
               <month>2</month>
               <year>2003</year>
            </date>
         </pub>
      </history>
   </fm>
   <bdy>
      <sec>
         <st>
            <p/>
         </st>
         <p>In the past few years, several novel autoantibodies (autoAbs) have been described in patients with rheumatoid arthritis (RA), including an autoAb to citrullinated antigens (anti-CCP) and anti-RA33 autoAb. It was our aim to assess the value of these two autoAbs in relation to rheumatoid factor (RF) in discriminating RA from non-RA in a cohort of patients with very early arthritis.</p>
         <p>Ninety-four patients with arthritis of less than 3 months' duration were included in this prospective study. Follow-up was for at least 1 year. Sixty-one patients had a final diagnosis of RA and 33 had other arthritides. Among the RA patients, RF was present in 34 (56%), anti-CCP in 18 (30%), and anti-RA33 in 15 (25%) at their first visit. Among the 33 non-RA patients, 6 were RF-positive, 3 had anti-RA33, and 1 had anti-CCP. Thus, anti-CCP was very specific for RA with a positive predictive value (PPV) of 95%, while RF and anti-RA33 were somewhat less specific, with PPVs of 85% and 83%, respectively. However, the co-occurrence of anti-RA33 and RF was observed exclusively in RA patients and thus had a PPV of 100% in this relatively small cohort of patients. In conclusion, these data suggest that the determination of autoantibodies such as anti-CCP and anti-A2/RA33 in addition to RF may be quite helpful in the early diagnosis of RA.</p>
      </sec>
   </bdy>
</art>
